• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用超临界流体技术制备的伊曲康唑固体分散体:制备、体外表征及在比格犬体内的生物利用度

Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs.

作者信息

Yin Xuezhi, Daintree Linda Sharon, Ding Sheng, Ledger Daniel Mark, Wang Bing, Zhao Wenwen, Qi Jianping, Wu Wei, Han Jiansheng

机构信息

Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery of Ministry of Education, Shanghai, People's Republic of China ; Changzhou Pharmaceutical Factory, Changzhou, People's Republic of China.

Crystec Pharma Tianjin Research Centre, Tianjin, People's Republic of China.

出版信息

Drug Des Devel Ther. 2015 May 28;9:2801-10. doi: 10.2147/DDDT.S81253. eCollection 2015.

DOI:10.2147/DDDT.S81253
PMID:26060397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4454206/
Abstract

This research aimed to develop a supercritical fluid (SCF) technique for preparing a particulate form of itraconazole (ITZ) with good dissolution and bioavailability characteristics. The ITZ particulate solid dispersion was formulated with hydroxypropyl methylcellulose, Pluronic F-127, and L-ascorbic acid. Aggregated particles showed porous structure when examined by scanning electron microscopy. Powder X-ray diffraction and Fourier transform infrared spectra indicated an interaction between ITZ and excipients and showed that ITZ existed in an amorphous state in the composite solid dispersion particles. The solid dispersion obtained by the SCF process improved the dissolution of ITZ in media of pH 1.0, pH 4.5, and pH 6.8, compared with a commercial product (Sporanox(®)), which could be ascribed to the porous aggregated particle shape and amorphous solid state of ITZ. While the solid dispersion did not show a statistical improvement (P=0.50) in terms of oral bioavailability of ITZ compared with Sporanox(®), the C max (the maximum plasma concentration of ITZ in a pharmacokinetic curve) of ITZ was raised significantly (P=0.03) after oral administration. Thus, the SCF process has been shown to be an efficient, single step process to form ITZ-containing solid dispersion particles with good dissolution and oral bioavailability characteristics.

摘要

本研究旨在开发一种超临界流体(SCF)技术,以制备具有良好溶出度和生物利用度特性的伊曲康唑(ITZ)颗粒剂。采用羟丙基甲基纤维素、泊洛沙姆F-127和L-抗坏血酸制备ITZ颗粒固体分散体。扫描电子显微镜检查显示聚集颗粒具有多孔结构。粉末X射线衍射和傅里叶变换红外光谱表明ITZ与辅料之间存在相互作用,并表明ITZ在复合固体分散体颗粒中以无定形状态存在。与市售产品(斯皮仁诺(®))相比,通过SCF工艺获得的固体分散体提高了ITZ在pH 1.0、pH 4.5和pH 6.8介质中的溶出度,这可能归因于ITZ的多孔聚集颗粒形状和无定形固态。虽然与斯皮仁诺(®)相比,固体分散体在ITZ的口服生物利用度方面没有统计学上的改善(P = 0.50),但口服给药后ITZ的Cmax(药代动力学曲线中ITZ的最大血浆浓度)显著提高(P = 0.03)。因此,SCF工艺已被证明是一种高效的单步工艺,可形成具有良好溶出度和口服生物利用度特性的含ITZ固体分散体颗粒。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/578ef973a59f/dddt-9-2801Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/f6691c31bb93/dddt-9-2801Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/de0eacf81020/dddt-9-2801Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/8c2aa3f05501/dddt-9-2801Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/531d8d417170/dddt-9-2801Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/0bfbbf9ade58/dddt-9-2801Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/1b7071664a52/dddt-9-2801Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/578ef973a59f/dddt-9-2801Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/f6691c31bb93/dddt-9-2801Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/de0eacf81020/dddt-9-2801Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/8c2aa3f05501/dddt-9-2801Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/531d8d417170/dddt-9-2801Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/0bfbbf9ade58/dddt-9-2801Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/1b7071664a52/dddt-9-2801Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/4454206/578ef973a59f/dddt-9-2801Fig7.jpg

相似文献

1
Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs.采用超临界流体技术制备的伊曲康唑固体分散体:制备、体外表征及在比格犬体内的生物利用度
Drug Des Devel Ther. 2015 May 28;9:2801-10. doi: 10.2147/DDDT.S81253. eCollection 2015.
2
Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.与伊曲康唑纳米混悬剂相比,伊曲康唑/Soluplus 挤出物的溶解和口服吸收增加。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1285-92. doi: 10.1016/j.ejpb.2013.03.002. Epub 2013 Apr 3.
3
Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.具有 pH 依赖性溶解度的难溶性药物口服生物利用度增强的强力干燥药物纳米混悬剂。
Int J Pharm. 2011 Jul 15;413(1-2):237-44. doi: 10.1016/j.ijpharm.2011.04.034. Epub 2011 Apr 21.
4
Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods.溶剂控制沉淀法和喷雾干燥法制备伊曲康唑固体分散体的表征及药代动力学研究
J Pharm Pharmacol. 2017 Dec;69(12):1707-1715. doi: 10.1111/jphp.12805. Epub 2017 Sep 5.
5
Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.吸入用伊曲康唑固体分散体,具有增强的溶解、溶解和分散性能。
Int J Pharm. 2012 May 30;428(1-2):103-13. doi: 10.1016/j.ijpharm.2012.03.002. Epub 2012 Mar 10.
6
Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole.使用浓度增强聚合物提高伊曲康唑生物利用度的无定形组合物。
Mol Pharm. 2008 Nov-Dec;5(6):968-80. doi: 10.1021/mp800042d.
7
Bioavailability enhancement of itraconazole-based solid dispersions produced by hot melt extrusion in the framework of the Three Rs rule.在“3R规则”框架下,通过热熔挤出法制备的基于伊曲康唑的固体分散体的生物利用度提高。
Eur J Pharm Sci. 2017 Mar 1;99:1-8. doi: 10.1016/j.ejps.2016.12.001. Epub 2016 Dec 9.
8
High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers.具有生物相容性稳定剂的雾化伊曲康唑纳米颗粒分散体具有高生物利用度。
Int J Pharm. 2008 Sep 1;361(1-2):177-88. doi: 10.1016/j.ijpharm.2008.05.003. Epub 2008 May 14.
9
Development of Itraconazole Tablets Containing Viscous KinetiSol Solid Dispersions: In Vitro and In Vivo Analysis in Dogs.含粘性 KinetiSol 固体分散体的伊曲康唑片的研制:犬体内外分析。
AAPS PharmSciTech. 2018 Jul;19(5):1998-2008. doi: 10.1208/s12249-017-0903-1. Epub 2017 Nov 30.
10
Development of novel itraconazole-loaded solid dispersion without crystalline change with improved bioavailability.研制新型伊曲康唑固体分散体,无晶型变化,生物利用度提高。
Arch Pharm Res. 2010 Aug;33(8):1217-25. doi: 10.1007/s12272-010-0812-2. Epub 2010 Aug 28.

引用本文的文献

1
Biocompatible Natural Polymer-Based Amorphous Solid Dispersion System Improving Drug Physicochemical Properties, Stability, and Efficacy.基于生物相容性天然聚合物的无定形固体分散体系统改善药物的物理化学性质、稳定性和疗效。
Polymers (Basel). 2025 Jul 28;17(15):2059. doi: 10.3390/polym17152059.
2
Significant Impact of Growth Medium on Itraconazole Susceptibility in Azole-Resistant Versus Wild-Type and Isolates.生长培养基对唑类耐药菌株与野生型菌株伊曲康唑敏感性的显著影响。
Int J Mol Sci. 2025 Jul 23;26(15):7090. doi: 10.3390/ijms26157090.
3
Machine learning analysis of drug solubility via green approach to enhance drug solubility for poor soluble medications in continuous manufacturing.

本文引用的文献

1
High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole.高速静电纺丝用于扩大生产伊曲康唑无定形固体分散体。
Int J Pharm. 2015 Mar 1;480(1-2):137-42. doi: 10.1016/j.ijpharm.2015.01.025. Epub 2015 Jan 14.
2
Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo.微环境pH调节的固体分散体用于提高难溶性弱碱性GT0918(一种正在研发的抗前列腺癌药物)的溶出度和生物利用度:制备、表征及体内评价
Int J Pharm. 2014 Nov 20;475(1-2):97-109. doi: 10.1016/j.ijpharm.2014.08.047. Epub 2014 Aug 27.
3
通过绿色方法对药物溶解度进行机器学习分析,以提高连续制造中难溶性药物的溶解度。
Sci Rep. 2025 Jul 17;15(1):26007. doi: 10.1038/s41598-025-11823-z.
4
Modification of biopharmaceutical parameters of flavonoids: a review.黄酮类化合物生物制药参数的修饰:综述
Front Chem. 2025 Apr 29;13:1602967. doi: 10.3389/fchem.2025.1602967. eCollection 2025.
5
Enhanced O/N separation by QuaternizedMatrimid/Multiwalled carbon nanotube mixed-matrix membrane.季铵化Matrimid/多壁碳纳米管混合基质膜增强的透氧/透氮分离性能
Heliyon. 2023 Nov 8;9(11):e21992. doi: 10.1016/j.heliyon.2023.e21992. eCollection 2023 Nov.
6
Amorphous Solid Dispersion as Drug Delivery Vehicles in Cancer.无定形固体分散体作为癌症治疗中的药物递送载体
Polymers (Basel). 2023 Aug 11;15(16):3380. doi: 10.3390/polym15163380.
7
Ternary Solid Dispersions: A Review of the Preparation, Characterization, Mechanism of Drug Release, and Physical Stability.三元固体分散体:制备、表征、药物释放机制及物理稳定性综述
Pharmaceutics. 2023 Aug 10;15(8):2116. doi: 10.3390/pharmaceutics15082116.
8
Improved Bioavailability of Poorly Water-Soluble Drug by Targeting Increased Absorption through Solubility Enhancement and Precipitation Inhibition.通过增强溶解度和抑制沉淀靶向提高吸收来改善难溶性药物的生物利用度
Pharmaceuticals (Basel). 2021 Dec 2;14(12):1255. doi: 10.3390/ph14121255.
9
Preparation of Solid Dispersions of Simvastatin and Soluplus Using a Single-Step Organic Solvent-Free Supercritical Fluid Process for the Drug Solubility and Dissolution Rate Enhancement.采用一步法无有机溶剂超临界流体工艺制备辛伐他汀与 Soluplus 的固体分散体以提高药物溶解度和溶出速率
Pharmaceuticals (Basel). 2021 Aug 25;14(9):846. doi: 10.3390/ph14090846.
10
Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.药物非晶态固体分散体:制备策略综述
Acta Pharm Sin B. 2021 Aug;11(8):2505-2536. doi: 10.1016/j.apsb.2021.05.014. Epub 2021 Jun 5.
Solid dispersion of berberine-phospholipid complex/TPGS 1000/SiO₂: preparation, characterization and in vivo studies.
盐酸小檗碱-磷脂复合物/TPGS1000/SiO₂ 固体分散体的制备、表征及体内研究。
Int J Pharm. 2014 Apr 25;465(1-2):306-16. doi: 10.1016/j.ijpharm.2014.01.023. Epub 2014 Jan 20.
4
Solid dispersion prepared by continuous cogrinding in an air jet mill.采用气流粉碎机连续共研磨制备固体分散体。
J Pharm Sci. 2013 Nov;102(11):4132-9. doi: 10.1002/jps.23731. Epub 2013 Sep 16.
5
Characterization and performance assessment of solid dispersions prepared by hot melt extrusion and spray drying process.热熔挤出和喷雾干燥工艺制备的固体分散体的特性和性能评估。
Int J Pharm. 2013 Nov 30;457(1):71-81. doi: 10.1016/j.ijpharm.2013.08.081. Epub 2013 Sep 6.
6
Formulation and in vivo human bioavailability of dissolving tablets containing a self-nanoemulsifying itraconazole solid dispersion without precipitation in simulated gastrointestinal fluid.含自纳米乳化伊曲康唑固体分散体且在模拟胃肠液中无沉淀的分散片的制剂及体内人体生物利用度
Eur J Pharm Sci. 2014 Jan 23;51:67-74. doi: 10.1016/j.ejps.2013.08.037. Epub 2013 Sep 5.
7
Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.伊曲康唑:治疗侵袭性和过敏性真菌感染的药理学和临床应用的最新进展。
Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):911-26. doi: 10.1517/17425255.2013.794785. Epub 2013 May 6.
8
Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.与伊曲康唑纳米混悬剂相比,伊曲康唑/Soluplus 挤出物的溶解和口服吸收增加。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1285-92. doi: 10.1016/j.ejpb.2013.03.002. Epub 2013 Apr 3.
9
Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry.二维高效液相色谱-串联质谱法同时定量检测人血浆中的唑类抗真菌药、抗生素、伊马替尼和雷特格韦。
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Mar 1;919-920:1-9. doi: 10.1016/j.jchromb.2012.12.028. Epub 2013 Jan 9.
10
Enhancing the bioavailability of magnolol in rabbits using melting solid dispersion with polyvinylpyrrolidone.利用聚乙烯吡咯烷酮熔融固体分散体提高兔体内厚朴酚的生物利用度。
Drug Dev Ind Pharm. 2014 Mar;40(3):330-7. doi: 10.3109/03639045.2012.760580. Epub 2013 Feb 1.